Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure.

"We are pleased that the FDA has approved the protocol for this Phase III study of farletuzumab in first-relapsed, platinum-sensitive ovarian cancer," stated Martin D. Phillips, M.D., Chief Medical Officer of Morphotek. "Physicians and patients do not have many good choices for treating ovarian cancer at this stage, and we are hopeful that some day farletuzumab may provide an option for ovarian cancer patients and their caregivers."

Morphotek is currently concluding a Phase II trial with farletuzumab as a single-agent and in combination with standard-of-care chemotherapy (carboplatin and taxane) in platinum-sensitive ovarian cancer patients experiencing a first relapse of their disease. The trial was designed to measure objective rate of response, and to compare the length of a patient's second remission with her first remission. Interim results from the study demonstrated an encouraging rate of durable objective response in patients on combination therapy. These findings prompted pursuit of a definitive pivotal study to evaluate the capacity of farletuzumab to benefit patients with ovarian cancer in a rigorously controlled manner.

The Phase III study, the design of which was agreed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, plac
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Today, ... announced the publication of a new eBook, Affordable ... many small business owners feel uncertain about how ... family, and their bottom line. , The new ... and helps businesses navigate their upcoming health insurance ...
(Date:8/20/2014)... By Dennis Thompson ... -- U.S. teen birth rates fell dramatically during the past ... dollars, a new government report shows. An estimated 4 ... the decline, according to researchers from the U.S. Centers for ... "leapt out at me from the report," said Bill Albert, ...
(Date:8/20/2014)... study of chronic users of codeine-containing cough syrups ... brain white matter and associates these changes with ... used diffusuion tensor imaging (DTI) (an MR imaging ... white matter integrity of chronic CCS users. Deficits ... including the inferior fronto-occipital fasciculus, which other studies ...
(Date:8/20/2014)... WEDNESDAY, Aug. 20, 2014 (HealthDay News) -- Loss of ... help explain why many seniors have trouble falling and ... patients, sleep disruption can be especially severe and often ... researchers. The investigators analyzed data from the Rush ... who enrolled at age 65 and are being followed ...
(Date:8/20/2014)... 20, 2014 Park Cities Pet Sitter ... Presents 4 Pets supply donation drive that benefits the animal ... national campaign that coincides with the Humane Society of the ... 2nd through 8th, 2014. , As part of their participation, ... and monetary donations for the Presents 4 Pets drive from ...
Breaking Medicine News(10 mins):Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4
... blood vessels open to treat heart disease are poorly ... Journal of Interventional Cardiology . A case report ... the Detroit Medical Center Cardiovascular Institute, and her colleagues ... the recently marketed Ion stent (Boston Scientific, Natick, MA) ...
... from the University of Sheffield has found that people are willing ... year, for greener urban spaces. Researchers surveyed the public in ... out how much extra they were willing to pay in council ... They found that people were willing to pay more for greener ...
... Young athletes who routinely take hits to the head could ... a concussion, according to the results of a new preliminary ... (URMC) said their findings could be a red flag for ... young people whose brains are still developing. The study ...
... HealthDay Reporter , WEDNESDAY, Nov. 16 (HealthDay News) ... is better at controlling a serious kidney complication from ... suggests. People taking mycophenolate were about half as ... taking azathioprine (Imuran), according to the researchers. "This ...
... 132,000 Internal medicine physician and medical student members of ... (D-PA) for urging the Joint Select Committee on Deficit ... PHYSICIAN PAYMENT INNOVATION ACT. This proposal repeals the ... better payment systems for physicians providing services to patients ...
... is the recipient of one of Canada,s top awards ... the mammalian immune system, Kubes will accept the 2011 ... Canadian Institutes of Health Research (CIHR) at a ceremony ... Kubes for winning this prestigious award," said the Honourable ...
Cached Medicine News:Health News:Public willing to pay more for greener urban spaces 2Health News:Public willing to pay more for greener urban spaces 3Health News:Routine Head Hits in Sports May Injure Brain, Experts Warn 2Health News:Newer Drug Seems Better at Controlling Lupus Kidney Complication 2Health News:Newer Drug Seems Better at Controlling Lupus Kidney Complication 3Health News:Internists 'applaud' Schwartz Proposal to prevent 'devastating' Medicare cuts 2Health News:University of Calgary researcher named Canada's Health Researcher of the Year 2Health News:University of Calgary researcher named Canada's Health Researcher of the Year 3
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
(Date:8/20/2014)... , August 20, 2014 ... report titled "Monochloroacetic Acid (MCA) Market for Cellulosics, Agrochemicals, ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... at USD 817.1 million in 2013 and is anticipated ... a CAGR of 3.6% during the forecast period from ...
(Date:8/20/2014)... -- Research and Markets has announced ... Care and Closure Market (Types, Applications, End User ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... their offering. The new report ... (types, applications, end user and geography) - Size, ...
Breaking Medicine Technology:Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... indicates that anti-inflammatory drugs may become a new tool ... leading global cause of death. In investigating a specific ... researchers used the Cardiochip, a gene analysis tool designed ... Center for Applied Genomics at The Children,s Hospital of ...
... March 14, 2012 OncoSec Medical Incorporated ... Medical System (OMS) ElectroOncology therapies to treat solid ... Institute in Santa Monica, CA, and Lakeland Comprehensive ... as enrolling sites, and investigators are screening patients ...
Cached Medicine Technology:Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 2Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Medicine Products: